Hasanzadeh A, Ebadati A, Dastanpour L, Aref A, Zangabad P, Kalbasi A
ACS Pharmacol Transl Sci. 2023; 6(12):1758-1779.
PMID: 38093832
PMC: 10714436.
DOI: 10.1021/acsptsci.3c00102.
Sun Y, Yao L, Wang C, Xiong B, Guo J, Wang L
J Oncol. 2022; 2022:6406122.
PMID: 35401749
PMC: 8991408.
DOI: 10.1155/2022/6406122.
Munoz-Galvan S, Carnero A
Cells. 2020; 9(6).
PMID: 32512891
PMC: 7349391.
DOI: 10.3390/cells9061402.
Bouberhan S, Philp L, Hill S, Al-Alem L, Rueda B
Cancers (Basel). 2020; 12(5).
PMID: 32403357
PMC: 7281458.
DOI: 10.3390/cancers12051206.
Bellio C, DiGloria C, Spriggs D, Foster R, Growdon W, Rueda B
Cancers (Basel). 2019; 11(11).
PMID: 31671803
PMC: 6896080.
DOI: 10.3390/cancers11111678.
Inhibition of mTORC1 in pediatric low-grade glioma depletes glutathione and therapeutically synergizes with carboplatin.
Poore B, Yuan M, Arnold A, Price A, Alt J, Rubens J
Neuro Oncol. 2018; 21(2):252-263.
PMID: 30239952
PMC: 6374766.
DOI: 10.1093/neuonc/noy150.
Can Stemness and Chemoresistance Be Therapeutically Targeted via Signaling Pathways in Ovarian Cancer?.
Roy L, Cowden Dahl K
Cancers (Basel). 2018; 10(8).
PMID: 30042330
PMC: 6116003.
DOI: 10.3390/cancers10080241.
Proteotranscriptomics Reveal Signaling Networks in the Ovarian Cancer Microenvironment.
Worzfeld T, Finkernagel F, Reinartz S, Konzer A, Adhikary T, Nist A
Mol Cell Proteomics. 2017; 17(2):270-289.
PMID: 29141914
PMC: 5795391.
DOI: 10.1074/mcp.RA117.000400.
NFκB Promotes Ovarian Tumorigenesis via Classical Pathways That Support Proliferative Cancer Cells and Alternative Pathways That Support ALDH Cancer Stem-like Cells.
House C, Jordan E, Hernandez L, Ozaki M, James J, Kim M
Cancer Res. 2017; 77(24):6927-6940.
PMID: 29074539
PMC: 5732863.
DOI: 10.1158/0008-5472.CAN-17-0366.
Personalized Medicine-Based Approach to Model Patterns of Chemoresistance and Tumor Recurrence Using Ovarian Cancer Stem Cell Spheroids.
Raghavan S, Mehta P, Ward M, Bregenzer M, Fleck E, Tan L
Clin Cancer Res. 2017; 23(22):6934-6945.
PMID: 28814433
PMC: 6330017.
DOI: 10.1158/1078-0432.CCR-17-0133.
The NF1 somatic mutational landscape in sporadic human cancers.
Philpott C, Tovell H, Frayling I, Cooper D, Upadhyaya M
Hum Genomics. 2017; 11(1):13.
PMID: 28637487
PMC: 5480124.
DOI: 10.1186/s40246-017-0109-3.
Regulation of CD44v6 expression in gastric carcinoma by the IL-6/STAT3 signaling pathway and its clinical significance.
Xu Y, Guo M, Yang L, Zhou F, Yu C, Wang A
Oncotarget. 2017; 8(28):45848-45861.
PMID: 28507278
PMC: 5542232.
DOI: 10.18632/oncotarget.17435.
Overexpression of Class III β-tubulin, Sox2, and nuclear Survivin is predictive of taxane resistance in patients with stage III ovarian epithelial cancer.
Du J, Li B, Fang Y, Liu Y, Wang Y, Li J
BMC Cancer. 2015; 15:536.
PMID: 26198101
PMC: 4511538.
DOI: 10.1186/s12885-015-1553-x.
YAP/TEAD co-activator regulated pluripotency and chemoresistance in ovarian cancer initiated cells.
Xia Y, Zhang Y, Yu C, Chang T, Fan H
PLoS One. 2014; 9(11):e109575.
PMID: 25369529
PMC: 4219672.
DOI: 10.1371/journal.pone.0109575.
A new spontaneously transformed syngeneic model of high-grade serous ovarian cancer with a tumor-initiating cell population.
McCloskey C, Goldberg R, Carter L, Gamwell L, Al-Hujaily E, Collins O
Front Oncol. 2014; 4:53.
PMID: 24672774
PMC: 3957277.
DOI: 10.3389/fonc.2014.00053.
Ovarian cancer stem cells: are they real and why are they important?.
Shah M, Landen C
Gynecol Oncol. 2013; 132(2):483-9.
PMID: 24321398
PMC: 4316675.
DOI: 10.1016/j.ygyno.2013.12.001.
